Abstract
Seventeen patients with malignant gliomas recurrent after chemotherapy and/ or radiation failure were treated with aziridinylbenzoquinone (AZQ) at a dose of 20-15 mg/M2 weekly for four weeks followed by a two week rest. Regression of disease was observed in four patients, 4/17 (24%) for 35, 15+,40+, and 10 weeks. Toxicity was limited to moderate reversible myelosuppression. AZQ in this dose and schedule has limited but definite activity in patients with malignant gliomas progressive after primary radiation therapy failure.
Similar content being viewed by others
References
Driscoll JS, Dudeck L, Congleton G, Geran RI: Potential CNS antitumor agents VI: Aziridinylbenzoquinones III. J Pharm Sci 68:185–188, 1979.
Baker LH, Samson M, Leichman C, Young J: Phase I evaluation of aziridinylbenzoquinones (NSC-182986) in a weekly IV. schedule. Proc AACR 22:189, 1981.
Levin VA, Wilson CB, Crafts D, Norman D, Hoffer P, Spire JP: Criteria for evaluating malignant brain tumor patients undergoing chemotherapy. J of Neurosurgery 47:325–329, 1977.
Eagen RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD: Preliminary communication-treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ; NSC-182986). Am J Clin Oncol. 6: 557–578, 1983.
Feun LG, Savaraj N, Bedirian AY et al.: Phase II study of 2, 5-diaziridinyl-3, 6-bis-carboethoxyamino-1, 4-benzoquinone (AZQ, NSC-182–986) in recurrent malignant gliomas. Proc Am Assoc Cancer Res 23:15, 1982.
Taylor S: Phase II trial of AZQ (Azioidinylbenzoquine; NSC-182986) in malignant gliomas. Southwest Oncology Group, personal, communication.
Feun LG, Yung W-KA, Leavens M E et al.: A phase II trial of 2,5,-diaziridinyl 3.6-bis (carboethoxy animo) 1,4-benzoquinom (AZQ, NSC 182986) in recurrent primary brain tumors. J Neuro-Oncology 2:13–17, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Decker, D.A., Al Sarraf, M., Kresge, C. et al. Phase 11 study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. J Neuro-Oncol 3, 19–21 (1985). https://doi.org/10.1007/BF00165167
Issue Date:
DOI: https://doi.org/10.1007/BF00165167